A new RNA-based Therapy (microRNA) Change Post-MI Remodeling?
A new RNA-based Therapy (microRNA) Change Post-MI Remodeling?
Phase 2 HF-REVERT trial tested a new RNA-based therapy designed to block harmful microRNA-132 activity involved in heart remodeling after myocardial infarction.
* The drug reduced circulating miR-132 levels, confirming biological activity, but did not significantly improve LV remodeling at 6 months.
* Included:
* Recent MI
* LVEF ≤ 45%
* Safety profile remained acceptable.
* Published May 10, 2026.
http://www.nature.com/
